Table 1 Laboratory investigation before and after three years of combined conventional and GH replacement therapy
From: Effect of growth hormone replacement therapy in a boy with Dent's disease: a case report
| Â | 24mo pre-GH | Baseline | 24 mo post-GH | 36mo post-GH |
|---|---|---|---|---|
| Â | Hydrochlorothiazide | Hydrochlorothiazide + phosphate + K-citrate +calcitriol+rhGH | Hydrochlorothiazide + phosphate +K-citrate +calcitriol+rhGH | Hydrochlorothiazide + phosphate +K-citrate +calcitriol+rhGH |
> 2 GH peaks at night (nl > 20 mU/L) | 22.0-28.0 | nd | nd | nd |
GH peaks with provocative stimuli (nl > 20 mU/L) | nd | nd | nd | 33 (2 mo without GH therapy) |
IGF-1 (9 y: nl 123-275 ng/ml) (11 y: 139-395 ng/ml) (12 y: 143-693 ng/ml) | nd | 122 (before GH therapy) | 300.5 - 496 (with GH therapy) | 90-125 (2 mo without GH therapy) |
Calcium (s) (nl 2.1-2.5 mmol/L) | 2.4 | 2.4 | 2.4 | 2.3 |
Phosphate (s) (nl 0.8-1.5 mmol/L) | 1.0 | 0.74 | 0.96 | 1-1.25 |
iPTH (nl 0.95-5.7 pmol/l) | n.d | 6.1 | n.d | 2.68 |
ALP (5-10 yr: 110-341 U/L) (Puberty: < 500) | 224.70 | 926.0 | 638 | 160-174 |
TRP (nl 85-98%) | 65-77 | 75 | 57 | 50-60 |
Creatinine clearance (nl 89-165 ml/min/1.73 m2) | 92.8 | 99.8 | 107 | 112.7 |
β2-microglobulin (nl < 0.03-0.37 mg/24 h) | 81.6 | nd | nd | nd |
Protein excretion (nl < 0.150 g/24 h) | 1.86 | 3.21 | 2.1 | 2.0-3.0 |
Calcium excretion (nl < 4 mg/kg/24 h) | 10.1 | 10.9 | 8.9 | 6.7-7.2 |